SEARCH:   Advanced

Blood, 15 July 2006, Vol. 108, No. 2, pp. 441-451. Prepublished online as a Blood First Edition Paper on March 23, 2006; DOI 10.1182/blood-2005-07-3011. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-07-3011v1 108/2/441    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hilden, J. M. Articles by Reaman, G. H. Search for Related Content PubMed PubMed Citation Articles by Hilden, J. M. Articles by Reaman, G. H. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group Joanne M. Hilden, Patricia A. Dinndorf, Sharon O. Meerbaum, Harland Sather, Doojduen Villaluna, Nyla A. Heerema, Ron McGlennen, Franklin O. Smith, William G. Woods, Wanda L. Salzer, Helen S. Johnstone, Zoann Dreyer, and Gregory H. Reaman From the Children's Hospital at the Cleveland Clinic, OH; Children's National Medical Center, Washington, DC; Children's Oncology Group (COG) Operations Center, Arcadia, CA; Columbus Children's Hospital, OH; University of Minnesota, Minneapolis; Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, OH; Children's Healthcare of Atlanta, GA; Keesler Medical Center, Keesler Air Force Base, Biloxi, MS; University of Illinois, Chicago; and Texas Children's Cancer Center at Baylor College of Medicine, Houston. Infant acute lymphoblastic leukemia (ALL) has a poor therapeutic outcome despite attempts to treat it based on prognostic factor–guided therapy. This is the first cooperative group trial characterizing all infants at the molecular level for MLL/11q23 rearrangement. All infants enrolled on Children's Cancer Group (CCG) 1953 were tested for MLL rearrangement by Southern blot and the 11q23 translocation partner was identified (4;11, 9;11, 11;19, or "other") by reverse-transcriptase polymerase chain reaction (PCR). One hundred fifteen infants were enrolled; overall event-free survival (EFS) was 41.7% (SD = 9.2%) and overall survival (OS) was 44.8% at 5 years. Five-year EFS for MLL-rearranged cases was 33.6% and for MLL-nonrearranged cases was 60.3%. The difference in EFS between the 3 major MLL rearrangements did not reach statistical significance. Multivariate Cox regression analyses showed a rank order of significance for negative impact on prognosis of CD10 negativity, age younger than 6 months, and MLL rearrangement, in that order. Toxicity was the most frequent cause of death. Relapse as a first event in CCG 1953 was later (median, 295 days) compared with CCG 1883 historic control (median, 207 days). MLL/11q23 rearrangement, CD10 expression, and age are important prognostic factors in infant ALL, but molecular 11q23 translocation partners do not predict outcome. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. H. van der Linden, M. G. Valsecchi, P. De Lorenzo, A. Moricke, G. Janka, T. M. Leblanc, M. Felice, A. Biondi, M. Campbell, I. Hann, et al. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol Blood, October 29, 2009; 114(18): 3764 - 3768. [Abstract] [Full Text] [PDF] R. K. Slany The molecular biology of mixed lineage leukemia Haematologica, July 1, 2009; 94(7): 984 - 993. [Abstract] [Full Text] [PDF] J. A. Ross Environmental and Genetic Susceptibility to MLL-Defined Infant Leukemia J Natl Cancer Inst Monographs, July 1, 2008; 2008(39): 83 - 86. [Abstract] [Full Text] [PDF] N. L. Seibel Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls Hematology, January 1, 2008; 2008(1): 374 - 380. [Abstract] [Full Text] [PDF] C.-H. Pui Central Nervous System Disease in Acute Lymphoblastic Leukemia: Prophylaxis and Treatment Hematology, January 1, 2006; 2006(1): 142 - 146. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020